Columbia, MD, United States of America

Lee-Cheng Liu


Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 1997-2001

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Lee-Cheng Liu: Innovator in Bioprocessing and Gene Therapy

Introduction

Lee-Cheng Liu is a notable inventor based in Columbia, MD (US). He has made significant contributions to the fields of bioprocessing and gene therapy, holding a total of 3 patents. His work focuses on innovative methods that enhance the production and treatment of biological materials.

Latest Patents

One of Liu's latest patents is a method of producing adenoviral vector stocks. This invention provides a systematic approach to cultivating cells that are permissive for adenoviral vector growth. The method involves culturing cells in a specific medium, perfusing fresh medium, and subsequently infecting the cells with adenoviral vectors to replicate and harvest them effectively. Another significant patent is a cell inoculation device designed for the safe and effective biotreatment of circulating fluids. This apparatus includes a conduit for fluid circulation, an oxygenator, a pump, a bioreactor unit, and a container for managing the fluid.

Career Highlights

Throughout his career, Lee-Cheng Liu has worked with prominent companies such as GenVec, Inc. and W. R. Grace Co. His experience in these organizations has contributed to his expertise in bioprocessing technologies and gene therapy innovations.

Collaborations

Liu has collaborated with notable professionals in his field, including Timothy Jon Perlman and Catherine A. Doyle. These collaborations have likely enriched his research and development efforts, leading to impactful inventions.

Conclusion

Lee-Cheng Liu's contributions to bioprocessing and gene therapy through his patents and collaborations highlight his role as an influential inventor. His innovative methods continue to advance the field and improve biotechnological applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…